These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 39159654)

  • 1. Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study.
    Ryckman TS; McQuaid CF; Cohen T; Menzies NA; Kendall EA
    Lancet Glob Health; 2024 Oct; 12(10):e1629-e1637. PubMed ID: 39159654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis.
    Ryckman TS; Schumacher SG; Lienhardt C; Sweeney S; Dowdy DW; Mirzayev F; Kendall EA
    Lancet Glob Health; 2024 Jun; 12(6):e995-e1004. PubMed ID: 38762299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis.
    Arinaminpathy N; Gomez GB; Sachdeva KS; Rao R; Parmar M; Nair SA; Rade K; Kumta S; Hermann D; Hanson C; Chin DP; Dewan P
    PLoS One; 2020; 15(3):e0230808. PubMed ID: 32218585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
    James LP; Klaassen F; Sweeney S; Furin J; Franke MF; Yaesoubi R; Chesov D; Ciobanu N; Codreanu A; Crudu V; Cohen T; Menzies NA
    PLoS Med; 2024 May; 21(5):e1004401. PubMed ID: 38701084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical cost dynamics for the treatment of rifampicin-resistant tuberculosis in children and adolescents in South Africa, India, and the Philippines.
    Wilkinson T; Garcia-Prats AJ; Sachs T; Paradkar M; Suryavanshi N; Kinikar A; Frias MV; Sinanovic E; Hesseling AC; Seddon JA; Palmer M
    PLoS One; 2024; 19(7):e0305930. PubMed ID: 39042708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
    Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
    BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
    Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
    Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
    Nsengiyumva NP; Campbell JR; Oxlade O; Vesga JF; Lienhardt C; Trajman A; Falzon D; Den Boon S; Arinaminpathy N; Schwartzman K
    PLoS Med; 2022 Jun; 19(6):e1004032. PubMed ID: 35696431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.
    Knight GM; Gomez GB; Dodd PJ; Dowdy D; Zwerling A; Wells WA; Cobelens F; Vassall A; White RG
    PLoS One; 2015; 10(12):e0145796. PubMed ID: 26717007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial.
    Rosu L; Madan JJ; Tomeny EM; Muniyandi M; Nidoi J; Girma M; Vilc V; Bindroo P; Dhandhukiya R; Bayissa AK; Meressa D; Narendran G; Solanki R; Bhatnagar AK; Tudor E; Kirenga B; Meredith SK; Nunn AJ; Bronson G; Rusen ID; Squire SB; Worrall E;
    Lancet Glob Health; 2023 Feb; 11(2):e265-e277. PubMed ID: 36565704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.
    Kendall EA; Shrestha S; Cohen T; Nuermberger E; Dooley KE; Gonzalez-Angulo L; Churchyard GJ; Nahid P; Rich ML; Bansbach C; Forissier T; Lienhardt C; Dowdy DW
    PLoS Med; 2017 Jan; 14(1):e1002202. PubMed ID: 28045934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
    Gomez GB; Siapka M; Conradie F; Ndjeka N; Garfin AMC; Lomtadze N; Avaliani Z; Kiria N; Malhotra S; Cook-Scalise S; Juneja S; Everitt D; Spigelman M; Vassall A
    BMJ Open; 2021 Dec; 11(12):e051521. PubMed ID: 34862287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
    Kendall EA; Malhotra S; Cook-Scalise S; Denkinger CM; Dowdy DW
    BMC Infect Dis; 2019 Sep; 19(1):794. PubMed ID: 31500572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target regimen profiles for tuberculosis treatment.
    Lienhardt C; Dooley KE; Nahid P; Wells C; Ryckman TS; Kendall EA; Davies G; Brigden G; Churchyard G; Cirillo DM; Di Meco E; Gopinath R; Mitnick C; Scott C; Amanullah F; Bansbach C; Boeree M; Campbell M; Conradie F; Crook A; Daley CL; Dheda K; Diacon A; Gebhard A; Hanna D; Heinrich N; Hesseling A; Holtzman D; Jachym M; Kim P; Lange C; McKenna L; Meintjes G; Ndjeka N; Nhung NV; Nyang'wa BT; Paton NI; Rao R; Rich M; Savic R; Schoeman I; Makokotlela BS; Spigelman M; Sun E; Svensson E; Tisile P; Varaine F; Vernon A; Diul MY; Kasaeva T; Zignol M; Gegia M; Mirzayev F; Schumacher SG
    Bull World Health Organ; 2024 Aug; 102(8):600-607. PubMed ID: 39070602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
    Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
    [No Abstract]   [Full Text] [Related]  

  • 18. The global impact of household contact management for children on multidrug-resistant and rifampicin-resistant tuberculosis cases, deaths, and health-system costs in 2019: a modelling study.
    Dodd PJ; Mafirakureva N; Seddon JA; McQuaid CF
    Lancet Glob Health; 2022 Jul; 10(7):e1034-e1044. PubMed ID: 35597248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trade-offs between cost and accuracy in active case finding for tuberculosis: A dynamic modelling analysis.
    Cilloni L; Kranzer K; Stagg HR; Arinaminpathy N
    PLoS Med; 2020 Dec; 17(12):e1003456. PubMed ID: 33264288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
    Ndjeka N; Campbell JR; Meintjes G; Maartens G; Schaaf HS; Hughes J; Padanilam X; Reuter A; Romero R; Ismail F; Enwerem M; Ferreira H; Conradie F; Naidoo K; Menzies D
    Lancet Infect Dis; 2022 Jul; 22(7):1042-1051. PubMed ID: 35512718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.